Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZ960 |
Synonyms | |
Therapy Description |
AZ960 is an ATP-competitive inhibitor of JAK2, which induces apoptosis and induces cell growth arrest (PMID: 21207414). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZ960 | AZ-960 | JAK2 Inhibitor - ATP competitive 15 | AZ960 is an ATP-competitive inhibitor of JAK2, which induces apoptosis and induces cell growth arrest (PMID: 21207414). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F | acute megakaryocytic leukemia | sensitive | AZ960 | Preclinical - Cell culture | Actionable | In a preclinical study, AZ960 treatment induced apoptosis, decreased Stat3/5 phosphorylation and downstream signaling, and inhibited proliferation of a megakaryoblastic leukemia cell line harboring JAK2 V617F in culture (PMID: 18775810). | 18775810 |
JAK2 R867Q | hematologic cancer | decreased response | AZ960 | Preclinical | Actionable | In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328). | 24398328 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|